Human cell-based anti-inflammatory effects of rosiglitazone

Area of Science:

• Immunology
• Cardiology
• Endocrinology

Background:

• C-X-C motif chemokine ligand 10 (CXCL10) is implicated in diabetes and diabetic cardiomyopathy.
• Inflammation involving CD4+ T cells, dendritic cells (DCs), and cardiomyocyte remodeling contributes to disease progression.
• Rosiglitazone (RGZ) possesses anti-inflammatory properties and can affect cardiomyocytes under inflammatory conditions.

Purpose of the Study:

• To investigate RGZ's effect on inflammation-induced secretion of CXCL10, IFNγ, TNFα, IL-6, and IL-8 by human CD4+ T cells and DCs.
• To assess RGZ's impact on IFNγ/TNFα-dependent signaling in human cardiomyocytes related to chemokine release.

Main Methods:

• Human CD4+ T cells and DCs were cultured in an inflammatory microenvironment and treated with RGZ (5 µM).
• Cytokine secretion was quantified using ELISA, mRNA expression via qPCR, and protein activation through Western blot.
• Immunofluorescence was employed to detect intracellular IFNγ/TNFα trafficking.

Main Results:

• RGZ inhibited CXCL10 release in CD4+ T cells and DCs, potentially via transcriptional mechanisms, and reduced TNFα in CD4+ T cells.
• In cardiomyocytes, RGZ impaired IFNγ/TNFα signal transduction by blocking Stat1 and NF-kB activation.
• RGZ significantly decreased CXCL10 expression, IL-6, and IL-8 release in cardiomyocytes.

Conclusions:

• RGZ demonstrates anti-inflammatory effects by inhibiting key Th1 biomarkers and signaling pathways.
• The findings suggest RGZ's potential therapeutic role in managing inflammation associated with diabetic cardiomyopathy.
• Further research into RGZ's anti-Th1 effects is warranted for predicting T2D and cardiovascular events.